The Respiratory Burst and Psoriasis

  • Rudolf E. Schopf


Psoriasis is a disease affecting about 1–2% of the population worldwide, similar to diabetes mellitus.1 It occurs somewhat more frequently in the white population than among Asians and Eskimos.1 The disease has two peaks of onset, an early one occurring around the age of 20 and a later one around 60.2 In early-onset psoriasis, 85% of patients exhibit the HLA Cw6 antigen; in the late-onset group, no such pattern of inheritance can be found.2


Phorbol Myristate Acetate Respiratory Burst Psoriatic Skin Mononuclear Leukocyte Pustular Psoriasis 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Christophers E, Krueger GG: Psoriasis, in Fitzpatrick TB, Eisen AZ, Wolff K, Freedberg IM, Austen KF (eds): Dermatology in General Medicine, ed 3. New York, McGraw-Hill, 1987, p 461.Google Scholar
  2. 2.
    Henseler T, Christophers E: Psoriasis of early and late onset. Characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 13: 450–456, 1985.PubMedGoogle Scholar
  3. 3.
    Farber EM, Nickoloff BJ, Recht B, Fräki JE: Stress, symmetry, and psoriasis: Possible role of neuropeptides. J Am Acad Dermatol 14: 305–311, 1986.PubMedGoogle Scholar
  4. 4.
    Pinkus H, Mehregan AH: The primary histologic lesion of seborrheic dermatitis and psoriasis. J Invest Dermatol 46: 109–116, 1966.PubMedGoogle Scholar
  5. 5.
    Kogoj F: Un cas de maladie de Hallopeau. Acta Derm Venereol (Stockh) 8: 1–12, 1928.Google Scholar
  6. 6.
    Lever WF, Schaumburg-Lever G: Histopathology of the Skin, ed 6. Philadelphia, Lippincott, 1983.Google Scholar
  7. 7.
    Braun-Falco O, Scherer R: Immunoinflammatory phenomena in psoriasis, in Beutner EH (ed): Autoimmunity in Psoriasis. Boca Raton, Florida, CRC Press, 1982, p 165.Google Scholar
  8. 8.
    Dahl MV: Immunology and papulosquamous diseases, in Stone J (ed): Dermatologie Immunology. St. Louis, CV Mosby, 1985, p 619.Google Scholar
  9. 9.
    Krueger GG, Eyre RW: Trigger factors in psoriasis, in Weinstein GD, Voorhees J J (eds): Dermatologie Clinics. Philadelphia, WB Saunders, 1984, vol 2, p 373.Google Scholar
  10. 10.
    Altmeyer P, Münz D, Holzmann H, Hör G: Functional studies of sessile macrophages in liver and spleen of psoriatics. Dermatologica 166: 15–22, 1983.PubMedGoogle Scholar
  11. 11.
    Altmeyer P, Münz DL, Chilf G, et al: Morphological and functional findings of fixed phagocytes in psoriatics. Arch Dermatol Res 275: 95–99, 1983.PubMedGoogle Scholar
  12. 12.
    Sedgwick JB, Hurd ER, Bergstresser PR: Abnormal granulocyte morphology in patients with psoriasis. Br J Dermatol 107: 165–172, 1982.PubMedGoogle Scholar
  13. 13.
    Greaves MW: Neutrophil polymorphonuclears, mediators and the pathogenesis of psoriasis. Br J Dermatol 109: 115–118, 1983.PubMedGoogle Scholar
  14. 14.
    Glinski W, Mansbridge J: Polymorphonuclear leukoctes in psoriasis. Cutis 30: 441–442, 1985.Google Scholar
  15. 15.
    Fräki JE, Jakoi L, Davies AO, et al: Polymorphonuclear leukocyte function in psoriasis. J Invest Dermatol 81: 254–257, 1985.Google Scholar
  16. 16.
    Bork K, Holzmann H: Phagozytoseleistung der neutrophilen Leukozyten bei der psoriatischen Entzündung. Arch Dermatol Forsch 251: 11–17, 1974.PubMedGoogle Scholar
  17. 17.
    Rupee M: Zur Ultrastruktur der spongiformen Pustel. Arch Klin Exp Dermatol 239: 30–49, 1970.Google Scholar
  18. 18.
    Tagami H, Ofuji S: A leukotactic factor in the stratum corneum of pustulosis palmaris et plantaris. Acta Derm Venereol (Stockh) 58: 401–405, 1978.Google Scholar
  19. 19.
    Schopf RE, Rehder M, Benes P, Et Al: Impaired function of numerically augmented Fc-receptors on granulocytes in a HLA B8+ patient with palmoplantar pustulosis. Arch Dermatol Res 279: 444– 448, 1987.Google Scholar
  20. 20.
    Babior BM: Oxygen-dependent microbial killing by phagocytes. N Engl J Med 298:659–668, 721–725, 1978.Google Scholar
  21. 21.
    Schopf RE, Hammann KP, Scheiner O, et al: Activation of human monocytes by both human ßlH and C3b. Immunology 46: 307–312, 1982.PubMedGoogle Scholar
  22. 22.
    Allen RC, Stjernholm RL, Steele RH: Evidence for the generation of an electronic excitation state(s) in human polymorphonuclear leukocytes and its participation in bactericidal activity. Biochem Biophys Res Commun 47: 679–684, 1972.PubMedGoogle Scholar
  23. 23.
    Allen RC, Loose LD: Phagocytic activation of a luminol-dependent chemiluminescence in rabbit alveolar and peritoneal machrophages. Biochem Biophys Res Commun 69: 245–252, 1976.PubMedGoogle Scholar
  24. 24.
    Allen RC: Biochemiexcitation, in Adam W, Cilento G (eds): Chemical and Biological Generation of Excited States. New York, Academic, 1982, p 309.Google Scholar
  25. 25.
    Schopf RE, Mattar J, Meyenburg W, et al: Measurement of respiratory burst in human monocytes and polymorphonuclear leukocytes by nitro blue tetrazolium reduction and chemiluminescence. J Immunol Method 67: 109–117, 1984.Google Scholar
  26. 26.
    Böyum A: Isolation of mononuclear cells and granulocytes from human blood. Scand J Clin Lab Invest (suppl) 97: 77–89, 1968.Google Scholar
  27. 27.
    Lehrer RI, Cohen L: Receptor-mediated regulation of superoxide production in human neutrophils stimulated by phorbol myristate acetate. J Clin Invest 68: 1314–1320, 1981.PubMedGoogle Scholar
  28. 28.
    Tucker SB, Pierre RV, Jordon RE: Rapid identification of monocytes in a mixed mononuclear cell preparation. J Immunol Method 14: 267–269, 1977.Google Scholar
  29. 29.
    Schopf RE, Straussfeld E: Stimulus-dependent increased generation of oxygen intermediates in monocytes and polymorphonuclear leukocytes in psoriasis. J Invest Dermatol 84: 73–76, 1985.PubMedGoogle Scholar
  30. 30.
    Geerdink JPM,, de Muldner PHM, Franzen MR et al: Monocyte function is normal in quiescent psoriasis. J Invest Dermatol 82: 122–125, 1984.PubMedGoogle Scholar
  31. 31.
    Bergmeyer H-U: Methoden der enzymatischen Analyse. Weinheim, Verlag Chemie, 1970, p 599.Google Scholar
  32. 32.
    Krueger GG, Jederberg WW, Ogden BE, Reese DL: Inflammatory and immune cell function in psoriasis. J Invest Dermatol 71: 195–201, 1978.PubMedGoogle Scholar
  33. 33.
    Herlin T, Borregaard N, Kragballe K: On the mechanisms of enhanced monocyte and neutrophil cytotoxicity in severe psoriasis. J Clin Invest 79: 104–108, 1982.Google Scholar
  34. 34.
    Kiistala U, Mustakallio KK: Dermo-epidermal separation with suction. J Invest Dermatol 48:466– 477, 1967.Google Scholar
  35. 35.
    Schopf RE, Hoffman A, Jung M, et al: Stimulation of T cells by autologous mononuclear leukocytes and epidermal cells in psoriasis. Arch Dermatol Res 279: 89–94, 1986.PubMedGoogle Scholar
  36. 36.
    Luger TA, Stadler BM, Katz SI, Oppenheim JJ: Epidermal cell (keratinocyte) derived thymocyte activating factor (ETAF). J Immunol 127: 1493–1498, 1981.PubMedGoogle Scholar
  37. 37.
    Kapp A, Luger TA, Schöpf E: Modulation of granulocyte oxidative response by mediators derived from human monocytes and epidermal cells. Abstracted J Invest Dermatol 89: 446, 1987.Google Scholar
  38. 38.
    Langhof H, Müller H: Leukotaktische Eigenschaften von Psoriasis-Schuppen. Hautarzt 17:101– 104, 1966.Google Scholar
  39. 39.
    Schwartze G, Wozniak K-D, Wohlrab W, Höfer H-W: Migration and Chemotaxis of donor leukocytes under the influence of psoriatic serum and psoriatic scale extracts. Dermatol Monatsschr 170: 637–641, 1984.PubMedGoogle Scholar
  40. 40.
    Schröder J-M, Christophers E: Identification of C5a desarg and an anionic neutrophil-activating peptide (ANAP) in psoriatic scales. J Invest Dermatol 87: 53–58, 1986.PubMedGoogle Scholar
  41. 41.
    Takematsu H, Ohkohchi K, Tagami H: Demonstration of anaphylatoxins C3a, C4a and C5a in the scales of psoriasis and inflammatory pustular dermatoses. Br J Dermatol 114: 1–6, 1986.PubMedGoogle Scholar
  42. 42.
    Takematsu H, Terni T, Ohkohchi K, et al: Presence of chemotactic peptides other than C5a anaphylatoxin in scales of psoriasis and sterile pustular dermatoses. Acta Derm Venereol (Stockh) 66: 93–97, 1986.Google Scholar
  43. 43.
    Brain SD, Camp RDR, Cunningham FM, et al: Leukotriene B4-like material in scale of psoriatic skin lesions. Br J Pharmacol 83: 313–317, 1984.PubMedGoogle Scholar
  44. 44.
    Grabbe J, Czarnetzki BM, Rosenbach T, Mardin M: Identification of chemotactic lipoxygenase products of arachidonate metabolism in psoriatic skin. J Invest Dermatol 82: 477–479, 1984.PubMedGoogle Scholar
  45. 45.
    Schopf RE, Rehder M, Bork K, Morsches B: Killing of normal and neoplastic epidermal cells by stimulated polymorphonuclear leukocytes in man. J Invest Dermatol 87: 165, 1986.Google Scholar
  46. 46.
    Nathan CF, Brukner LH, Silverstein SC, Cohn ZA: Extracellular cytolysis by activated mac-rophages and granulocytes. J Exp Med 149: 84–99, 1979.PubMedGoogle Scholar
  47. 47.
    Silny W, Pehamberger H, Zielinsky C, Gschnait F: Effect of PUVA treatment on the locomotion of polymorphonuclear leukocytes and mononuclear cells in psoriasis. J Invest Dermatol 7b5: 187–188, 1980.Google Scholar
  48. 48.
    Preissner WC, Schröder J-M, Christophers E: Altered PMN responses in psoriasis. Br J Dermatol 109: 1–8, 1983.PubMedGoogle Scholar
  49. 49.
    Csatö M, Dobozy A, Hunyadi J, et al: PMN Chemotaxis and chemotactic factor generation by Con A-stimulated peripheral blood mononuclear cells in patients with psoriasis. Arch Dermatol Res 271: 259–264, 1981.PubMedGoogle Scholar
  50. 50.
    Wahba A, Cohen HA, Bar-Eli M, Gallily R: Enhanced chemotactic and phagocytic activities of leukocytes in psoriasis vulgaris. J Invest Dermatol 71: 186–188, 1978.PubMedGoogle Scholar
  51. 51.
    Langner A, Chorzelski TP, Fraczykowska S, et al: Is chemotactic activity of polymorphonuclear leukocytes increased in psoriasis? Arch Dermatol Res 275: 226–228, 1983.PubMedGoogle Scholar
  52. 52.
    Fogh K, Ternowitz T, Kragballe K, Herlin T: Chemotactic lipoxygenase products in sera from patients with psoriasis. Arch Dermatol Res 278: 173–176, 1986.PubMedGoogle Scholar
  53. 53.
    Ternowitz T, Therstrup-Pedersen K: Neutrophil and monocyte Chemotaxis in pustulosis palmo-plantaris and pustular psoriasis. Br J Dermatol 113: 507–513, 1985.PubMedGoogle Scholar
  54. 54.
    Czarnetzki B: Increase monocyte Chemotaxis towards leukotriene B4 and platelet activating factor in patients with inflammatory dermatoses. Clin Exp Immunol 54: 486–492, 1983.PubMedGoogle Scholar
  55. 55.
    Sedgwick JB, Bergstresser PR, Hurd ER: Increased granulocyte adherence in psoriasis and psoriatic arthritis. J Invest Dermatol 74: 81–84, 1980.PubMedGoogle Scholar
  56. 56.
    Majewski S, Jablonska S, Langner A, Pawinska M, Szmurto A: The adherence to human endo-thelium and plastic of neutrophils from psoriatic patients, and the effects of psoriatic patients’ sera on normal neutrophils. Br J Dermatol 112: 655–662, 1985.PubMedGoogle Scholar
  57. 57.
    Bloomfield FJ, Young MM: Enhanced release of inflammatory mediators from lithium-stimulated neutrophils in psoriasis. Br J Dermatol 109: 9–13, 1983.PubMedGoogle Scholar
  58. 58.
    Glinski W, Barszcs D, Janczura E, et al: Neutral proteinases and other neutrophil enzymes in psoriasis, and their relation to disease activity. Br J Dermatol 111: 147–154, 1984.PubMedGoogle Scholar
  59. 59.
    Moszczynski P, Legiec C, Lisiewicz J: Acid phosphatase of neutrophils in peripheral blood of patients with psoriasis. Dermatol Monatsschr 170: 371–375, 1984.PubMedGoogle Scholar
  60. 60.
    Jain VK, Gupta V, Verma KC, Saini AS: NADPH oxidase and myeloperoxidase activity in psoriasis leukocytes. J Dermatol 12: 425–428, 1985.PubMedGoogle Scholar
  61. 61.
    Koh MS, Majewski BJ, Rhodes EL: Increased macrophage activity in psoriasis. Acta Derm Venereol (Stockh) 6b5: 194–198, 1985.Google Scholar
  62. 62.
    Lundin A, Hakansson L., Hällgren R, Et Al: Increased in vivo secretory activity of neutrophil granulocytes in patients with psoriasis and palmoplantar pustulosis. Arch Dermatol Res 277:179– 184, 1985.Google Scholar
  63. 63.
    Schopf RE, Müller F-J, Benes P, Morsches B: Augmented G-6-PDH activity and normal penetra-tion of metabolism of dehydroepiandrosterone in mononuclear leukocytes in psoriasis. Arch Der-matol Res 278: 393–397, 1986.Google Scholar
  64. 64.
    Krueger GG, Jederberg WW: Monocyte function in patients with psoriasis as assessed by chem- iluminescence and monokine production. Clin Res 27: 137, 1979.Google Scholar
  65. 65.
    Bar-Eli M, Gallily R, Cohen HA, Wahba A: Monocyte function in psoriasis. J Invest Dermatol 73: 147–149, 1979.PubMedGoogle Scholar
  66. 66.
    Lundin A, Hakansson L, Hällgren R, et al: Studies on the phagocytic activity of the granulocytes in psoriasis and palmoplantar pustulosis. Br J Dermatol 109: 539–547, 1983.PubMedGoogle Scholar
  67. 67.
    Herlin T, Kragballe K; Enhanced monocyte and neutrophil cytotoxicity and normal cyclic nu-cleotide levels in severe psoriasis. Br J Dermatol 105: 405–410, 1981.PubMedGoogle Scholar
  68. 68.
    Breathnach SM, Carrington P, Black MM: Neutrophil leukocyte migration in psoriasis vulgaris. J Invest Dermatol 76: 271–274, 1981.PubMedGoogle Scholar
  69. 69.
    Guillot B, Guilhou J, Vendrei JP, Meynadier J: Neutrophil Chemotaxis in psoriasis before and after PUVA therapy. Arch Dermatol Res 275: 19–22, 1983.PubMedGoogle Scholar
  70. 70.
    Cunningham FM, Wong E, Woollard PM, Greaves MW: The chemokinetic response of psoriatic and normal polymorphonuclear leukocytes to arachidonic acid lipoxygenase products. Arch Der-matol Res 278: 270–273, 1986.Google Scholar
  71. 71.
    Geerdink JPM, Troost PW, Schalwijk J, et al: The metabolic burst in polymorphonuclear leuko-cytes from patients with quiescent psoriasis. Br J Dermatol 112: 387–392, 1985.PubMedGoogle Scholar
  72. 72.
    Meuret G, Schmitt E, Hagedorn M: Monocytopoiesis in chronic exzematous diseases, psoriasis vulgaris and mycosis fungoides. J Invest Dermatol 66: 22–28, 1976.PubMedGoogle Scholar
  73. 73.
    Brigelius R: Mixed disulfides: Biological functions and increase in oxidative stress, in Sies H (ed): Oxidative Stress. London, Academic, 1985, p 243.Google Scholar
  74. 74.
    Voorhees JJ: Leukotrienes and other lipoxygenase products in the pathogenesis and therapy of psoriasis and other dermatoses. Arch Dermatol 119: 541–547, 1983.PubMedGoogle Scholar
  75. 75.
    Higgs GA: Arachidonic acid metabolism in leukocytes, in Karnovsky ML, Bolis L (eds): Phagocy-tosis—Past and Future. New York, Academic, 1982, p 105.Google Scholar
  76. 76.
    Csatö M, Dobozy A, Simon N: Nitroblue tetrazolium reductive activity of polymorphonuclear leukocytes in the blood and in the skin in psoriasis. Z Hautkr 58: 1731–1739, 1983.PubMedGoogle Scholar
  77. 77.
    Cotterill JA, Roberts MM, Freeman R, et al: Aspects of polymorph function in psoriasis. Proc R Soc Med 67: 874–875, 1974.PubMedGoogle Scholar
  78. 78.
    Miyachi Y, Niwa Y: Effects of psoriatic sera on the generation of oxygen intermediates bz normal polymorphonuclear leukocytes. Arch Dermatol Res 275: 23–26, 1983.PubMedGoogle Scholar
  79. 79.
    Herlin T, Borregaard N: Increased rate of opsonization of zymosan by serum from patients with psoriasis. Arch Dermatol Res 273: 343–345, 1982.PubMedGoogle Scholar
  80. 80.
    Sedgwick JB, Bergstresser PR, Hurd ER: Increased superoxide generation by normal granulocytes incubated in sera from patients with psoriasis. J Invest Dermatol 76: 158–163, 1981.PubMedGoogle Scholar
  81. 81.
    Marghescu S, Braun-Falco O: Quantitatives Verhalten von Immunoglobulinen and Komplement bei Psoriasis. Arch Klin Exp Dermatol 238: 417–427, 1970.PubMedGoogle Scholar
  82. 82.
    Kapp A, Wokalek H, Schöpf E: Involvement of complement in psoriasis and atopic dermatitis. Arch Dermatol Res 277: 359–361, 1985.PubMedGoogle Scholar
  83. 83.
    Ottkohchi K, Takematsu H, Tagami H: Increased anaphylatoxins (C3a and C4a) in psoriatic sera. Br J Dermatol 113: 189–196, 1985.Google Scholar
  84. 84.
    Guilhou J-J, Clot J, Meynadier J, Lapinski H: Immunological aspects of psoriasis. Br J Dermatol 94: 501–507, 1976.PubMedGoogle Scholar
  85. 85.
    Negrosanti M, Fanti PA, Gasponi A, Et Al: IgE serum levels in psoriasis. Dermatologica 163:474– 455, 1981.Google Scholar
  86. 86.
    Chen Z-Y, Aninsworth K, Khan T, et al: Immunoglobulin E in psoriasis is elevated by paper radioimmunosorbent and paper enzyme-immunosorbent tests. Arch Derm Venereol (Stockh) 65: 14–18, 1985.Google Scholar
  87. 87.
    Kapp A, Kemper A, Schöpf E, Deicher H: Detection of circulation immune complexes in patients with atopic dermatitis in psoriasis. Acta Derm Venereol (Stockh) 66: 121–126, 1986.Google Scholar
  88. 88.
    Westphal H-J, Schütt C, Hartwich M, et al: Evidence of circulating immune complexes in the sera of patients with psoriasis. Dermatol Monatsschr 168: 624–630, 1982.PubMedGoogle Scholar
  89. 89.
    Laurent MR, Panayi GS, Shepherd P: Circulating immune complexes, serum immunoglobulins, and acute phase proteins in psoriasis and psoriatic arthritis. Ann Rheum Dis 40: 66–69, 1981.PubMedGoogle Scholar
  90. 90.
    Hall RP, Peck GL, Lawley TJ: Circulating Ig A immune complexes in patients with psoriasis. J Invest Dermatol 80: 465–468, 1983.PubMedGoogle Scholar
  91. 91.
    Marley WM, Belew PW, Rosenberg EW, et al: Abnormalities in the alternative pathway of complement in psoriasis. J Invest Dermatol 76: 303, 1981.Google Scholar
  92. 92.
    Krogh HK, Tonder O: Antibodies in psoriatic scales. Scand J Immunol 2: 45–51, 1973.PubMedGoogle Scholar
  93. 93.
    Kaneko R, Muramatsu R, Takahashi Y, Miura Y: Extractable immune complex in soluble sub-stances from psoriatic scales. Arch Dermatol Res 276: 45–51, 1984.PubMedGoogle Scholar
  94. 94.
    Jones P, Kumar V: A solid-phase chemiluminescence immunoassay for determination of IgG in eluates of psoriatic scales. J Immunol Method 70: 185–192, 1984.Google Scholar
  95. 95.
    Takematsu H, Suzuki R, Tagami H, Kumagai K: Interleukin-l-like activity in horny layer extracts. Dermatologica 172: 236–240, 1986.PubMedGoogle Scholar
  96. 96.
    Fräki JE, Lazarus GS, Gilgor RS, et al: Correlation of epidermal plasminogen activator activity with disease activity in psoriasis. Br J Dermatol 108: 39–44, 1983.PubMedGoogle Scholar
  97. 97.
    Grondahl-Hansen J, Nielsen LS, Kristensen P, et al: Plasminogen activator in psoriatic scales is of the tissue-type PA as identified by monoclonal antibodies. Br J Dermatol 113: 257–263, 1985.PubMedGoogle Scholar
  98. 98.
    Stüttgen G, Würdemann I: Zur Darstellung der katheptischen Endopeptidase in der normalen menschlichen Haut und bei Dermatosen. Arch Klin Exp Dermatol 208: 192–198, 1957.Google Scholar
  99. 99.
    Katayama H, Kawada A: Exacerbation of psoriasis induced by indomethacin. J Dermatol (Tokyo) 8: 323–337, 1981.Google Scholar
  100. 100.
    Reshad H, GK Hargreaves GK, Vickers CFH: Generalized pustular psoriasis precipitated by phenylbutazone and oxyphenbutazone. Br J Dermatol 108: 111–113, 1983.Google Scholar
  101. 101.
    Kragballe K, Herlin T: Benoxyprofen improves psoriasis. Arch Dermatol 119: 548–552, 1983.PubMedGoogle Scholar
  102. 102.
    Skott A, Mobacken H, Starmark JE: Exacerbation of psoriasis during lithium treatment. Br J Dermatol 96: 445–448, 1977.PubMedGoogle Scholar
  103. 103.
    Skoven I, Thormann I: Lithium compound treatment and psoriasis. Arch Dermatol 115:1185– 1187, 1979.Google Scholar
  104. 104.
    S0ndergaard J, Wadskov S, Aerenlund- Jensen H, Mikkelsen HI: Aggravation of psoriasis and occurrence of psoriasiform cutaneous eruptions induced by practolol. Acta Derm Venereol (Stockh) 56: 239–243, 1976.Google Scholar
  105. 105.
    Halevy S, Reuerman EJ: Psoriasiform eruption induced by propranolol. Cutis 24: 95–99, 1979.PubMedGoogle Scholar
  106. 106.
    Forn J: Lithium and cyclic AMP, in Johnson FN (ed): Lithium Research and Therapy. London, Academic, 1975, p 485.Google Scholar
  107. 107.
    Voorhees JJ, Duell EA: Psoriasis as a possible defect of the adenyl cyclase-cyclic AMP cascade. Arch Dermatol 104: 352–358, 1971.PubMedGoogle Scholar
  108. 108.
    Bourne HR, Lichtenstein LM, Melmon KL, et al: Modulation of inflammation and immunity by cyclic AMP. Science 184: 19–28, 1974.PubMedGoogle Scholar
  109. 109.
    Rothstein G, Clarkson DR, Larsen W, et al: Effect of lithium on neutrophil mass and production. N Engl J Med 298: 178–180, 1978.PubMedGoogle Scholar
  110. 110.
    Glinski W, Barszcz D, Jablonska S, et al: Leukophoresis for treatment of psoriasis. Arch Dermatol Res 278: 6–12, 1985.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1988

Authors and Affiliations

  • Rudolf E. Schopf
    • 1
  1. 1.Department of DermatologyJohannes Gutenberg UniversityMainzWest Germany

Personalised recommendations